GlobeNewsWire
12 Jun 2026, 00:00 UTC · 14w ago
Verdict
Headline takes no side. We score HCM +1.00 across four claims — strongly bullish.
+1.00strongly bullish
More positive than 98% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
The Phase III ESLIM-02 study of sovleplenib met its primary endpoint, showing a 66% durable response rate versus 15% for placebo in wAIHA patients.
More positive than 99% of claims this week
The China National Medical Products Administration (NMPA) has accepted and granted priority review of the New Drug Application (NDA) for sovleplenib.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 93% of claims this week
Sovleplenib demonstrated a favorable safety profile with fewer Grade ≥3 adverse events compared to the placebo group (43% vs 59%).
More positive than 77% of claims this week
The drug showed efficacy in patients who had previously received rituximab therapy, maintaining a 69% durable response rate.
More positive than 64% of claims this week
Which stocks this story touches
More positive than 98% of ticker scores this week
The company announced positive Phase III trial results for sovleplenib and received priority review from the NMPA.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Globe News Wire
5h ago
+34.6%
Price agrees with the score
$14.37 vs $10.68 close before publication (Jun 11) · not market-adjusted
HCM chart →
